C
Changchang Liu
Researcher at Harvard University
Publications - 5
Citations - 218
Changchang Liu is an academic researcher from Harvard University. The author has contributed to research in topics: Cyclin A & Abemaciclib. The author has an hindex of 3, co-authored 5 publications receiving 97 citations.
Papers
More filters
Journal ArticleDOI
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.
Marc Hafner,Caitlin E. Mills,Kartik Subramanian,Chen Chen,Mirra Chung,Sarah A. Boswell,Robert A. Everley,Changchang Liu,Charlotte S. Walmsley,Dejan Juric,Peter K. Sorger +10 more
TL;DR: Five different phenotypic and biochemical assays are used to compare approved inhibitors of cyclin-dependent kinases 4/6-collectively regarded as breakthroughs in the treatment of hormone receptor-positive breast cancer to uncover underappreciated differences in CDK4/6 inhibitor activities with potential importance in treating human patients.
Journal ArticleDOI
The Dark Kinase Knowledgebase: An online compendium of knowledge and experimental results of understudied kinases
Matthew E. Berginski,Nienke Moret,Changchang Liu,Dennis Goldfarb,Peter K. Sorger,Shawn M. Gomez +5 more
TL;DR: A data resource, the Dark Kinase Knowledgebase (DKK), that is specifically focused on providing data and reagents for understudied kinases to the broader research community, and seeks to continually support and enhance knowledge on potentially high-impact druggable targets.
Posted ContentDOI
Exploring the understudied human kinome for research and therapeutic opportunities
Nienke Moret,Changchang Liu,Benjamin M. Gyori,John A. Bachman,Albert Steppi,Rahil Taujale,Liang-Chin Huang,Clemens B. Hug,Matthew E. Berginski,Shawn M. Gomez,Natarajan Kannan,Peter K. Sorger +11 more
TL;DR: A re-analysis of the kinome as a whole and criteria for creating an inclusive set of 710 kinase domains as well as a curated set of 557 protein kinase like (PKL) domains are described.
Posted ContentDOI
A resource for exploring the understudied human kinome for research and therapeutic opportunities
Nienke Moret,Changchang Liu,Benjamin M. Gyori,John A. Bachman,Albert Steppi,Clemens B. Hug,Rahil Taujale,Liang-Chin Huang,Matthew E. Berginski,Shawn M. Gomez,Natarajan Kannan,Peter K. Sorger +11 more
TL;DR: In this paper, the authors describe objective criteria for refining the definition of the human kinome to comprise an extended set of 710 kinase domains and a more narrowly curated set of 557 protein kinase like (PKL) domains.
Posted ContentDOI
Multi-omics profiling establishes the polypharmacology of FDA Approved CDK4/6 inhibitors and the potential for differential clinical activity
Marc Hafner,Marc Hafner,Caitlin E. Mills,Kartik Subramanian,Chen Chen,Mirra Chung,Sarah A. Boswell,Robert A. Everley,Changchang Liu,Charlotte S. Walmsley,Dejan Juric,Peter K. Sorger +11 more
TL;DR: Five different phenotypic and biochemical assays are used to compare approved inhibitors of cyclin-dependent kinases 4/6 – collectively regarded as breakthroughs in the treatment of hormone receptor-positive breast cancer – to uncover under-appreciated differences in CDK4/6 inhibitor activities with potential importance in treating human patients.